The design of chronic toxicology studies of monoclonal antibodies: Implications for the reduction in use of non-human primates
Authors:
- Kathryn L. ChapmanKCKathryn L. Chapman
- Laura AndrewsLALaura Andrews
- Jeffrey J. BajramovicJBJeffrey J. Bajramovic
- Paul BaldrickPBPaul Baldrick
- Lauren E. BlackLBLauren E. Black
- Christopher J. BowmanChristopher J. Bowman
- Lorrene A. BuckleyLBLorrene A. Buckley
- Lee A. ConeyLCLee A. Coney
- Jessica CouchJCJessica Couch
- A. Maggie DempsterADA. Maggie Dempster
- Lolke de HaanLHLolke de Haan
- Keith JonesKJKeith Jones
- 1 March 2012
- journal article
- research article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 62 (2) , 347-354
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Safety evaluation of biological drugs: What are toxicology studies in primates telling us?Regulatory Toxicology and Pharmacology, 2011
- Preclinical development of monoclonal antibodiesmAbs, 2009
- Spending on new drug development1Health Economics, 2009
- Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: Is 6 months still appropriate?Regulatory Toxicology and Pharmacology, 2008
- Preclinical safety testing of monoclonal antibodies: the significance of species relevanceNature Reviews Drug Discovery, 2007